WO1998018960A1 - Procede destine a mettre en evidence l'etat d'une cellule maligne et procede de traitement - Google Patents
Procede destine a mettre en evidence l'etat d'une cellule maligne et procede de traitement Download PDFInfo
- Publication number
- WO1998018960A1 WO1998018960A1 PCT/FR1997/001960 FR9701960W WO9818960A1 WO 1998018960 A1 WO1998018960 A1 WO 1998018960A1 FR 9701960 W FR9701960 W FR 9701960W WO 9818960 A1 WO9818960 A1 WO 9818960A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- product
- expression
- nucleus
- cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 75
- 230000008569 process Effects 0.000 title claims abstract description 17
- 230000003211 malignant effect Effects 0.000 title claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 62
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 37
- 201000011510 cancer Diseases 0.000 claims abstract description 19
- 230000036210 malignancy Effects 0.000 claims abstract description 16
- 238000011065 in-situ storage Methods 0.000 claims abstract description 12
- 230000008521 reorganization Effects 0.000 claims abstract description 12
- 230000001093 anti-cancer Effects 0.000 claims abstract description 8
- 238000002372 labelling Methods 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 86
- 210000004940 nucleus Anatomy 0.000 claims description 57
- 230000014509 gene expression Effects 0.000 claims description 33
- 210000000349 chromosome Anatomy 0.000 claims description 32
- 239000000523 sample Substances 0.000 claims description 24
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 18
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 18
- 108020004414 DNA Proteins 0.000 claims description 17
- 210000001519 tissue Anatomy 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 9
- 108091093105 Nuclear DNA Proteins 0.000 claims description 8
- 230000022131 cell cycle Effects 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 7
- 230000002093 peripheral effect Effects 0.000 claims description 7
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 6
- RURLVUZRUFHCJO-UHFFFAOYSA-N Chromomycin A3 Natural products COC(C1Cc2cc3cc(OC4CC(OC(=O)C)C(OC5CC(O)C(OC)C(C)O5)C(C)O4)c(C)c(O)c3c(O)c2C(=O)C1OC6CC(OC7CC(C)(O)C(OC(=O)C)C(C)O7)C(O)C(C)O6)C(=O)C(O)C(C)O RURLVUZRUFHCJO-UHFFFAOYSA-N 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 3
- 238000007901 in situ hybridization Methods 0.000 claims description 3
- 108090001008 Avidin Proteins 0.000 claims description 2
- 210000003855 cell nucleus Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims 2
- 102000003992 Peroxidases Human genes 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000004458 analytical method Methods 0.000 description 15
- 230000000875 corresponding effect Effects 0.000 description 14
- 239000013598 vector Substances 0.000 description 11
- 230000001629 suppression Effects 0.000 description 10
- 230000005760 tumorsuppression Effects 0.000 description 9
- 230000004913 activation Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102100021838 E3 ubiquitin-protein ligase SIAH1 Human genes 0.000 description 6
- 101100203238 Homo sapiens SIAH1 gene Proteins 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 101150069431 rbr-2 gene Proteins 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 101100041257 Chlorobaculum tepidum (strain ATCC 49652 / DSM 12025 / NBRC 103806 / TLS) rub2 gene Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 102000013415 peroxidase activity proteins Human genes 0.000 description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 108700025694 p53 Genes Proteins 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108091007914 CDKs Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 210000005053 lamin Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 101710116362 E3 ubiquitin-protein ligase sina Proteins 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 241000702620 H-1 parvovirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241001362551 Samba Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000037280 Trisomy Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 230000021572 chromosome movement towards spindle pole Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001317 epifluorescence microscopy Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 101150060022 med gene Proteins 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 108010066082 tartrate-sensitive acid phosphatase Proteins 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Definitions
- the present invention relates to a method for treating cells having a disorganization of the nucleus, characterized in that the expression of the product of the gene p21WAFl or an equivalent product is caused, or the product of the gene is introduced or the equivalent product
- the genome exposure test for DNase I has been modified compared to that described by Puck (Puck et al., 1991).
- the cells are fixed in 4% deformed paraformaldehyde / PBS (PBS: phosphate buffered saline) and stored at -80 ° C.
- PBS phosphate buffered saline
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP52014598A JP2001503261A (ja) | 1996-10-31 | 1997-10-31 | 悪性細胞の状態の検証法および治療法 |
DE69735636T DE69735636T2 (de) | 1996-10-31 | 1997-10-31 | Verfahren zur bestimmung des malignen zellezustands und verfahren zur behandlung |
EP97913233A EP0941364B1 (fr) | 1996-10-31 | 1997-10-31 | Procede destine a mettre en evidence l'etat d'une cellule maligne et procede de traitement |
CA002269865A CA2269865A1 (fr) | 1996-10-31 | 1997-10-31 | Procede destine a mettre en evidence l'etat d'une cellule maligne et procede de traitement |
US09/297,069 US6277575B1 (en) | 1996-10-31 | 1997-10-31 | Process aimed at evidencing the state of a malignant cell |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9613326A FR2755148B1 (fr) | 1996-10-31 | 1996-10-31 | Procede destine a mettre en evidence l'etat d'une cellule maligne et procede de traitement |
FR96/13326 | 1996-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998018960A1 true WO1998018960A1 (fr) | 1998-05-07 |
Family
ID=9497231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1997/001960 WO1998018960A1 (fr) | 1996-10-31 | 1997-10-31 | Procede destine a mettre en evidence l'etat d'une cellule maligne et procede de traitement |
Country Status (8)
Country | Link |
---|---|
US (1) | US6277575B1 (fr) |
EP (1) | EP0941364B1 (fr) |
JP (1) | JP2001503261A (fr) |
AT (1) | ATE322553T1 (fr) |
CA (1) | CA2269865A1 (fr) |
DE (1) | DE69735636T2 (fr) |
FR (1) | FR2755148B1 (fr) |
WO (1) | WO1998018960A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ849200A0 (en) * | 2000-06-30 | 2000-07-27 | Cea Technologies Inc. | Unsupervised scene segmentation |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0500290A2 (fr) * | 1991-02-22 | 1992-08-26 | Regents Of The University Of California | Coloration de chromosomes particuliers pour détection des réarrangements génétiques |
US5264343A (en) * | 1990-08-31 | 1993-11-23 | Eleanor Roosevelt Institute | Method for distinguishing normal and cancer cells |
WO1994019492A1 (fr) * | 1993-02-24 | 1994-09-01 | Mayo Foundation For Medical Education And Research | Instabilite genomique specifique a une tumeur constituant un indicateur pronostique |
WO1995009928A1 (fr) * | 1993-10-06 | 1995-04-13 | The Regents Of The University Of California | Procedes de detection de deletions chromosomiques associees au cancer par hybridation in situ |
WO1995013375A1 (fr) * | 1993-11-10 | 1995-05-18 | The Johns Hopkins University | Waf1 anti-tumoral |
WO1996025507A2 (fr) * | 1995-02-17 | 1996-08-22 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Procedes de preparation et d'utilisation de vecteurs adenoviraux recombines |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817462A (en) * | 1995-02-21 | 1998-10-06 | Applied Spectral Imaging | Method for simultaneous detection of multiple fluorophores for in situ hybridization and multicolor chromosome painting and banding |
US5506098A (en) * | 1991-09-04 | 1996-04-09 | Daikin Industries, Ltd. | In situ hybridization method |
US5707808A (en) * | 1996-04-15 | 1998-01-13 | The Regents Of The University Of California | Optical selection and collection of DNA fragments |
-
1996
- 1996-10-31 FR FR9613326A patent/FR2755148B1/fr not_active Expired - Fee Related
-
1997
- 1997-10-31 DE DE69735636T patent/DE69735636T2/de not_active Expired - Fee Related
- 1997-10-31 US US09/297,069 patent/US6277575B1/en not_active Expired - Fee Related
- 1997-10-31 EP EP97913233A patent/EP0941364B1/fr not_active Expired - Lifetime
- 1997-10-31 AT AT97913233T patent/ATE322553T1/de not_active IP Right Cessation
- 1997-10-31 WO PCT/FR1997/001960 patent/WO1998018960A1/fr active IP Right Grant
- 1997-10-31 JP JP52014598A patent/JP2001503261A/ja not_active Ceased
- 1997-10-31 CA CA002269865A patent/CA2269865A1/fr not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264343A (en) * | 1990-08-31 | 1993-11-23 | Eleanor Roosevelt Institute | Method for distinguishing normal and cancer cells |
EP0500290A2 (fr) * | 1991-02-22 | 1992-08-26 | Regents Of The University Of California | Coloration de chromosomes particuliers pour détection des réarrangements génétiques |
WO1994019492A1 (fr) * | 1993-02-24 | 1994-09-01 | Mayo Foundation For Medical Education And Research | Instabilite genomique specifique a une tumeur constituant un indicateur pronostique |
WO1995009928A1 (fr) * | 1993-10-06 | 1995-04-13 | The Regents Of The University Of California | Procedes de detection de deletions chromosomiques associees au cancer par hybridation in situ |
WO1995013375A1 (fr) * | 1993-11-10 | 1995-05-18 | The Johns Hopkins University | Waf1 anti-tumoral |
WO1996025507A2 (fr) * | 1995-02-17 | 1996-08-22 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Procedes de preparation et d'utilisation de vecteurs adenoviraux recombines |
Non-Patent Citations (3)
Title |
---|
HAAG M ET AL: "Reverse transformation and genome exposure in the C6 glial tumor cell line", CANCER INVESTIGATION, vol. 12, no. 1, 1994, pages 33 - 45, XP002035346 * |
NEMANI M ET AL: "Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression", PROC. NATL. ACAD. SCI. USA, vol. 93, August 1996 (1996-08-01), pages 9039 - 42, XP002035347 * |
WALDMAN T ET AL: "Uncoupling of S phase and mitosis induced by antcancer agents lacking p21", NATURE, vol. 381, June 1996 (1996-06-01), pages 713 - 16, XP002035345 * |
Also Published As
Publication number | Publication date |
---|---|
FR2755148B1 (fr) | 1999-01-29 |
US6277575B1 (en) | 2001-08-21 |
JP2001503261A (ja) | 2001-03-13 |
DE69735636T2 (de) | 2007-04-05 |
FR2755148A1 (fr) | 1998-04-30 |
DE69735636D1 (de) | 2006-05-18 |
EP0941364B1 (fr) | 2006-04-05 |
CA2269865A1 (fr) | 1998-05-07 |
ATE322553T1 (de) | 2006-04-15 |
EP0941364A1 (fr) | 1999-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shinde et al. | Transglutaminase-2 facilitates extracellular vesicle-mediated establishment of the metastatic niche | |
Xu et al. | Super-resolution imaging reveals the evolution of higher-order chromatin folding in early carcinogenesis | |
Nagy et al. | Connexin26 in adult rodent central nervous system: demonstration at astrocytic gap junctions and colocalization with connexin30 and connexin43 | |
Micchelli et al. | Rasp, a putative transmembrane acyltransferase, is required for Hedgehog signaling | |
Wang et al. | MyoD is a 3D genome structure organizer for muscle cell identity | |
JP5130042B2 (ja) | 核形態型に基づく幹細胞を同定するための方法 | |
EP1789802B1 (fr) | Vimentine phosphorylee comme marqueur de l'agressivite et/ou l'invasivite des tumeurs | |
Fu et al. | Foxp1 is indispensable for ductal morphogenesis and controls the exit of mammary stem cells from quiescence | |
EP2066806A2 (fr) | Test pharmaco diagnostique ciblant l'oncologie | |
Basta et al. | A Sall1-NuRD interaction regulates multipotent nephron progenitors and is required for loop of Henle formation | |
Jung et al. | Novel cancer gene variants and gene fusions of triple-negative breast cancers (TNBCs) reveal their molecular diversity conserved in the patient-derived xenograft (PDX) model | |
Tarin | Inappropriate gene expression in human cancer and its far-reaching biological and clinical significance | |
US20090304662A1 (en) | Methods for Identifying and Targeting Tumor Stem Cells Based on Nuclear Morphology | |
Linos et al. | Expanding the molecular diversity of CIC-rearranged sarcomas with novel and very rare partners | |
Maire et al. | Complex rearrangement of chromosomes 19, 21, and 22 in Ewing sarcoma involving a novel reciprocal inversion–insertion mechanism of EWS–ERG fusion gene formation: a case analysis and literature review | |
EP0941364B1 (fr) | Procede destine a mettre en evidence l'etat d'une cellule maligne et procede de traitement | |
Cheng et al. | Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer | |
EP1220950B9 (fr) | Marqueurs genetiques de la toxicite, preparation et utilisation | |
US20070298444A1 (en) | Methods and Compositions for Use in Evaluating and Treating Neoplastic Disease Conditions | |
O’Sullivan | Pediatric soft tissue tumor pathology: a happy morpho-molecular union | |
Cohn et al. | Delineating spatial cell-cell interactions in the solid tumour microenvironment through the lens of highly multiplexed imaging | |
EP3131930B1 (fr) | Anticorps reconnaissant le domaine central de l'adn polymerase pol theta et leurs utilisations pour le diagnostic du cancer | |
Laurans | Functional genomics of Krit1, the gene mutated in cerebral cavernous malformation | |
Askari | Characterization of the tumor suppressor activity of the FHIT gene in association with application of innovative detection technologies | |
FR2811335A1 (fr) | Methode de determination d'un modele cellulaire in vitro permettant de mimer le profil d'expression d'un gene d'interet dans une cellule in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2269865 Country of ref document: CA Ref country code: CA Ref document number: 2269865 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 520145 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 1998 520145 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997913233 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09297069 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1997913233 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997913233 Country of ref document: EP |